CKD: Dapagliflozin Offers Benefits Regardless of Diabetes Status

Takeaway

• Dapagliflozin lowers the risks of major adverse kidney and cardiovascular (CV) events and all-cause mortality in patients with chronic kidney disease (CKD), regardless of type 2 diabetes (T2D) status.

• These benefits also extend to patients with a broad range of underlying causes of CKD other than diabetic nephropathy (DN), including those with primary glomerulonephritides and ischaemic or hypertensive kidney disease.

Why this matters

• Dapagliflozin may provide substantial cardiorenal benefit to a broad range of patients with impaired kidney function and proteinuria, including patients with non-diabetic CKD.

Study design

• In DAPA-CKD trial, 4304 patients with an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73m² and a urinary albumin-to-creatinine ratio of 200-5000 mg/g were randomly assigned (1:1) to receive dapagliflozin or placebo in addition to standard of care.

• This prespecified analysis of the DAPA-CKD trial investigated whether the presence or absence of T2D at baseline and the underlying aetiology of kidney disease modified the effects of dapagliflozin.

• Primary composite outcome: sustained ≥50% eGFR decline, end-stage kidney disease (ESKD) and renal or CV death.

• Funding: AstraZeneca.

Key results

• Overall, 2906 (68%) patients had T2D, of whom 396 (14%) had CKD attributed to causes other than DN.

• Dapagliflozin reduced the risk of the primary composite outcome in patients with T2D (HR, 0.64; 95% CI, 0.52-0.79) and in those without T2D (HR, 0.50; 95% CI, 0.35-0.72; P_interaction=.24).

• Similar results were seen for the secondary outcomes in patients with T2D vs those without:

  • sustained ≥50% eGFR decline, ESKD and renal death (HR, 0.57; 95% CI, 0.45-0.73 vs HR, 0.51; 95% CI, 0.34-0.75; P_interaction=.57);

  • CV death or hospitalisation for HF (HR, 0.70; 95% CI, 0.53-0.92 vs HR, 0.79; 95% CI, 0.40-1.55; P_interaction=.78); and

  • all-cause mortality (HR, 0.74; 95% CI, 0.56-0.98 vs HR, 0.52; 95% CI, 0.29-0.93; P_interaction=.25).

• The effect of dapagliflozin on the primary outcome was consistent in patients with DN (HR, 0.63; 95% CI, 0.51-0.78), glomerulonephritides (HR, 0.43; 95% CI, 0.26-0.71), ischaemic or hypertensive CKD (HR, 0.75; 95% CI, 0.44-1.26) and CKD of other or unknown causes (HR, 0.58; 95% CI, 0·29-1·19; P_interaction=.53), with similar consistency seen across the secondary outcomes.

Limitations

• T2D diagnosis was based on investigator-reported diagnosis or glycated haemoglobin values and not on more conventional tests.

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

© 2021 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Sarfaroj Khan. CKD: Dapagliflozin Offers Benefits Regardless of Diabetes Status - Medscape - Jan 22, 2021.